Thank you.
Good afternoon everyone.
to, pointing regarding this which the Profound but not by include call may treatment start efficacy pain is statements the and BPH, forward-looking and limited and of me prostate out technology uterine conference that will include, of cancer, Let Profound’s regarding fibroids in palliative expectations its osteoma. business, osteoid
anticipates, words can believes, such negative such always, or not certain might, by be identified taken, would, but scheduled, including be intends, or will, actions, could, forward-looking expects, proposes occur statements or contemplates, plans, variations variations as words achieved. use or Often, as and events expected, of states be may, the of results phrases that
of management. Such are statements expectations based on current the
in differ regarding including materially risk growth a and factors, and the events call specified factors affecting equity circumstances risks conference markets and certain generally by known company, device forward-looking may with as could or risks occur and at and uncertainties and the economic unknown dates associated medical discussed this industry, result competition. of all not The the
required No differ Profound statement forward-looking from events to has factors to important could applicable those forward-looking guaranteed, actual to differ laws. that by results as Although or securities estimated actions, be results intended. or can described anticipated, identify cause in other may or statements, events actions, there that factors attempted materially cause except those from be
new or than whether by as undertakes on any statements, or obligation result update they required Forward-looking of to revise only statements are made, the speak no as information, and otherwise, Profound of which law. as events date forward-looking other future a publicly
Profound of tissue. to to ablation and story disease who the of develops those would business. markets to moment the benefit like Profound summarize incision-free customizable for new our the therapies For take a I are
rectum a surgeon-defined technology is ultrasound control. closed-loop preserve are We prostate and MRI, temperature volume patient's robotically the while a trans-urethral real-time The CE technology and ablation is functional XXX-K provide TULSA-PRO of predictable customizable commercializing Canada combines cleared and designed FDA. driven actively and natural the radiation-free Healthcare approved TULSA-PRO currently marked, to to feedback help urethra by that the protecting abilities.
We an that treatment for powder of innovative are Sonalleve also CE mesothesis. pain commercializing marked platform fibroids of is therapeutic uterine bone the treatment and
obtained by has the Products China exemption humanitarian Medical uterine for also under device a of of Administration osteoma. the treatment approved for recently been the osteoid FDA National Sonalleve fibroids and non-invasive approval has treatment
in not impact to we have and HDE expect making our it company are in for material this approval on XXXX. While term later do is a U.S. its significant commercial we launch for FDA revenues the a preparations near milestone
Aaron Financial Executive With that I and the over On call Profound’s are Dr. Davidson, turn the representing Officer the today call Chief Vice Arun said Senior of will to the President Officer; company’s and Chief Aaron. Menawat, company Corporate Development. now